Nuformix plc (LON:NFX – Get Free Report)’s share price was down 6.9% on Wednesday . The stock traded as low as GBX 0.15 and last traded at GBX 0.15. 6,983,824 shares were traded during mid-day trading, a decline of 78% from the average session volume of 31,040,061 shares. The stock had previously closed at GBX 0.16.
Nuformix Stock Up 6.5%
The company has a 50 day simple moving average of GBX 0.18 and a 200-day simple moving average of GBX 0.20. The stock has a market cap of £3.86 million, a price-to-earnings ratio of -5.05 and a beta of 1.54.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
